Lenalidomide - Celgene Corporation
Alternative Names: CC-5013; CDC-501; CDC-5013; ENMD-0997; IMiD-1; IMiD-3; Ladevina; Revimid™; REVLIMIDLatest Information Update: 28 Feb 2024
At a glance
- Originator Celgene Corporation
- Developer Baylor College of Medicine; BeiGene; Celgene Corporation; Dana-Farber Cancer Institute; Groupe dEtude des Lymphomes de lAdulte; H. Lee Moffitt Cancer Center and Research Institute; Helsinki University Central Hospital; Indiana University School of Medicine; IRCCS San Raffaele; Massachusetts General Hospital; National Cancer Institute (USA); Nordic MDS Study Group; Novartis; Ohio State University Comprehensive Cancer Center; Peking Union Medical College Hospital; Roche; Roswell Park Cancer Institute; Royal Marsden NHS Foundation Trust; SCRI Development Innovations; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of California, Davis; University of Florida; University of Wuerzburg; Washington University School of Medicine; Weill Cornell Medical College
- Class 2 ring heterocyclic compounds; Antineoplastics; Imides; Isoindoles; Piperidones; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cell proliferation inhibitors; Immunomodulators; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes
- Registered Adult T-cell leukaemia-lymphoma
- Preregistration Non-Hodgkin's lymphoma
- Phase III Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
- Phase II Acute myeloid leukaemia; Bladder cancer; Histiocytosis; Hodgkin's disease; Myelofibrosis; POEMS syndrome; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Phase I/II Non-small cell lung cancer
- No development reported Cancer; Chronic myeloid leukaemia; Eye neoplasms; Glioblastoma; Peripheral T-cell lymphoma; Prostate cancer; Solid tumours
- Discontinued Colorectal cancer; Heart failure; Inflammation; Liver cancer; Malignant melanoma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in USA (PO, Capsule)
- 31 Dec 2023 Beigene and Celgene Corporation terminates the license and supply agreement covering REVLIMID and VIDAZA as part of the settlement agreement
- 09 Dec 2023 Efficacy and immunogenicity data from a phase III Myeloma XI trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)